Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2006
08/22/2006CA2157836C L-carnitine salt and cosmetic and pharmaceutical compositions containing same for treating dermatoses
08/22/2006CA2118792C Immunopotentiating and infection protective agent and production thereof
08/22/2006CA2044468C Canine granulocyte macrophage colony stimulating factor
08/18/2006CA2498623A1 Treatment of onychomycosis
08/17/2006WO2006086773A2 Polyamine analogs as modulators of cell migration and cell motility
08/17/2006WO2006086764A2 Methods and compounds for the treatment of obesity and obesity-related disorders
08/17/2006WO2006086750A1 Liquid formulations for treatment of diseases or conditions
08/17/2006WO2006086744A1 Formulations for ocular treatment
08/17/2006WO2006086734A1 Substituted propane phosphinic acid esters
08/17/2006WO2006086727A2 Treating diabetes with glucagon-like peptide-1 secretagogues
08/17/2006WO2006086707A2 Extracts of asteraceae containing reduced levels of phototoxic thiophene derivatives and methods for preparing same
08/17/2006WO2006086698A2 Treating microvasculature diseases with acetyl cholinesterase inhibitors
08/17/2006WO2006086693A2 Medical devices
08/17/2006WO2006086680A1 Methods of making pravastatin sodium
08/17/2006WO2006086643A1 Method and composition for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite
08/17/2006WO2006086634A2 Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
08/17/2006WO2006086633A2 Substituted fused [1,2]imidazo[4,5-c] ring compounds and methods
08/17/2006WO2006086623A2 Drug composition and method for treating malaria and malignancy
08/17/2006WO2006086617A2 Polyethylene oxide polymers including anti-inflammatory glycodendrons
08/17/2006WO2006086613A2 2-METHYLENE-19-NOR- (20S-24S) - 1α, 25-D IHYDROXYVITAMIN-D2
08/17/2006WO2006086609A2 Inhibitors of tryptase
08/17/2006WO2006086608A1 2-METHYLENE-19-NOR-(20S-24EPI)-1α,25-DIHYDROXYVITAMIN-D2
08/17/2006WO2006086600A1 Proteasome inhibitors and methods of using the same
08/17/2006WO2006086562A2 Phenylazetidinone derivatives
08/17/2006WO2006086539A1 Pyridopyrazolopyrimidine compounds and their uses as anti-cancer and anti-diabete drugs
08/17/2006WO2006086500A2 Compositions and methods for treating vascular, autoimmune and inflammatory diseases
08/17/2006WO2006086498A2 Treatment of vascular, autoimmune and inflammatory diseases using low dosages of impdh inhibitors
08/17/2006WO2006086484A1 Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer
08/17/2006WO2006086464A2 Dihydroquinazolinones as 5ht modulators
08/17/2006WO2006086454A2 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
08/17/2006WO2006086452A1 Methods for treating visual disorders
08/17/2006WO2006086449A2 Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
08/17/2006WO2006086447A2 Pyridazine derivatives and their use as therapeutic agents
08/17/2006WO2006086422A2 Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase
08/17/2006WO2006086372A2 Compositions and methods for treatment of neurological symptoms associated with alcohol-withdrawal and for convulsive seizure
08/17/2006WO2006086358A2 Mitotic kinesin inhibitors
08/17/2006WO2006086303A1 Method for the mitigation of symptoms of contact lens related dry eye
08/17/2006WO2006086270A1 Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
08/17/2006WO2006086255A2 Inhibitors of checkpoint kinases
08/17/2006WO2006086250A2 A catheter lock solution comprising citrate and a paraben
08/17/2006WO2006086229A1 The use of selective p2x7 receptor antagonists
08/17/2006WO2006086172A1 Cci-779 polymorph and use thereof
08/17/2006WO2006086144A2 Methods for treating cancer and other pathological proliferating disorders by inhibiting mitosis using pyrrolo[2,3-d]pyrimidines
08/17/2006WO2006086130A2 Process for crystallizing lactose particles for use in pharmaceutical formulations
08/17/2006WO2006086108A2 Use of inhibitors of soluble epoxide hydrolase to synergize activity of cox and 5-lox inhibitors
08/17/2006WO2006086103A2 Synthesis of inhibitors of p90rsk
08/17/2006WO2006086038A1 Methods and related compositions for reduction of fat and skin tightening
08/17/2006WO2006086012A2 Antibiotic compound
08/17/2006WO2006085988A1 Methods for treating parkinson’s disease
08/17/2006WO2006085932A2 Anti-viral uses of borinic acid complexes
08/17/2006WO2006085840A1 Skin-protective polymer for use in teat care compositions
08/17/2006WO2006085815A1 Thiazole derivatives, their process for their preparation and their use in therapy
08/17/2006WO2006085692A1 Crystal of 4(3h)-quinazolinone derivative
08/17/2006WO2006085689A1 Anticancer agent to be combined with telomelysin
08/17/2006WO2006085688A1 Psychogenic pain therapeutic agent
08/17/2006WO2006085687A1 Composition containing dihomo-ϝ-linolenic acid (dgla) as the active ingredient
08/17/2006WO2006085686A1 Remedy for neurogenic pain
08/17/2006WO2006085685A1 Pyrazole compound
08/17/2006WO2006085672A2 Production of polyunsaturated fatty acids using novel cell treatment method
08/17/2006WO2006085655A1 Ointment
08/17/2006WO2006085607A1 Plant component-containing emulsion preparation and method for producing the same
08/17/2006WO2006085562A1 Composition for preventing and/or treating metabolic syndrome and insulin resistance syndrome
08/17/2006WO2006085521A1 Medicinal composition for transdermal absorption containing opipid receptor antagonist, method of producing the same and method of promoting the transdermal absorption of the antagonist
08/17/2006WO2006085517A1 Ointment preparation or suppository for pdt based on chlorin or porphyrin derivative
08/17/2006WO2006085510A1 Remedy for irritable bowel syndrome
08/17/2006WO2006085497A1 Tablet disintegrating in the oral cavity
08/17/2006WO2006085346A1 Mixtures of fatty acid glycerides from c1 to c22 to improve zootechnical performances and/or the health of the intestine of animals
08/17/2006WO2006085337A1 Parenteral combination therpy for infective conditions with drug resistant bacterium
08/17/2006WO2006085335A2 Pharmaceutical composition of acid labile substances
08/17/2006WO2006085330A2 Use of protein tyrosine kinase inhibitors for the treatment of leiomyomas
08/17/2006WO2006085219A2 6-ether/thioether-purines as topoisomerase ii catalytic inhibitors and their use in therapy
08/17/2006WO2006085217A2 Solid adsorbates of hydrophobic drugs
08/17/2006WO2006085216A1 Substituted hydroxyethylamines
08/17/2006WO2006085212A2 Condensed isoxaline derivatives as inhibitors of phosphodiesterase type-iv
08/17/2006WO2006085199A1 Piperazine derivatives
08/17/2006WO2006085168A2 Solid oral dosage forms of ziprasidone containing colloidal silicone dioxide
08/17/2006WO2006085138A1 Treatment product for animals and means for preparing same
08/17/2006WO2006085118A2 Dihydroimidazothiazole derivatives
08/17/2006WO2006085112A1 Anthranilic acid derivatives as hm74a receptor agonists
08/17/2006WO2006085111A1 Anthranilic acid derivatives active at the hm74a receptor
08/17/2006WO2006085108A1 Awthranilic acid derivatives and their use in treatment of diseases of lipid metabolism, in particular dyslipidaemia
08/17/2006WO2006085102A1 Combination of methylxanthine compounds and steroids to treat chronic respiratory diseases
08/17/2006WO2006085096A1 Ligands for g-protein coupled receptors
08/17/2006WO2006085089A1 Solid dispersion of hydrophobic bioactive
08/17/2006WO2006085067A1 Atm inhibitors
08/17/2006WO2006085033A2 Pharmaceutical compositions for the treatment of prostate cancer
08/17/2006WO2006085013A2 Use of silymarine and/or the constituents thereof as promoters of the pigmentation of the skin or hair
08/17/2006WO2006084996A1 Substituted pyrroles, compositions containing same, method for making same and use thereof
08/17/2006WO2006084975A1 Derivatives of n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine (amide, thiourea and urea) as cannabinoid cb1 receptor antagonists
08/17/2006WO2006084934A1 Use of thiadiazolidine-derived compounds as neurogenic agents
08/17/2006WO2006084917A1 Non steroidal glucocorticoid receptor modulators
08/17/2006WO2006084913A2 Device for treatment of rectal disorders, and manufacturing process for the same, involving nitric oxide
08/17/2006WO2006084912A1 Device method, and use for treatment of neuropathy involving nitric oxide
08/17/2006WO2006084909A1 Device for treatment of disorders in the oral cavity with nitric oxide, and manufacturing process for the same
08/17/2006WO2006084904A1 Tetrahydropyridothiophenes as antripoliferative agents for the treatment of cancer
08/17/2006WO2006084894A2 Use of tryptophan in combination with caffeine and taurine, foodstuff and beverage containing said combination
08/17/2006WO2006084882A2 Substituted 4-(indol-3-yl)quinazolines and their use
08/17/2006WO2006084869A1 Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer
08/17/2006WO2006084854A2 [1,2,4]-dithiazoli(di)ne derivatives, inducers of gluthathione-s-transferase and nadph quinone oxido-reductase, for prophylaxis and treatment of adverse conditions associated with cytotoxicity in general and apoptosis in particular
08/17/2006WO2006084835A1 N-(3-(imidazo [1,5-a]pyrimidin-4-yl)phenyl]-sulfonamides and n-[3-(imidazo[1,5-a]pyrimidin-4-yl)-phenyl]-carboxamides and their use as gabaa receptor modulators